03 August 2009
Martinsried, Germany - Affectis Pharmaceuticals, a biopharmaceutical company developing novel drugs for the treatment of psychiatric and inflammatory disorders, today announced the appointment of Alex Martin as Chief Financial Officer. Mr. Martin brings over 20 years experience in the life sciences industry, most recently serving as Chief Operating Officer of Intercept Pharmaceuticals.
Herbert Stadler, founder and CEO of Affectis, commented, "We are please to have Alex join our team as he brings experience as both a CFO and an operating manager which will be invaluable as we continue to advance our pipeline and invest in our programs further."
| File | File size |
|---|---|
 Affectis - Alex Martin CFO Aug 3 2009 | 25 Kb |
08 July 2009
Martinsried, Germany - Affectis Pharmaceuticals announced today that it has been awarded a €550.000 grant from the Bavarian Technology Promotion Program (BayTP) of the Bavarian Ministry of Economics. For a period of two years, the grant will fund the identification and characterization of novel drug candidates for the treatment of major depression.
Depression is a disabling disease that affects more than 121 million individuals globally, according to the World Health Organization (WHO). Current therapies fail to address unmet medical needs such as faster onset of action, better side-effect profile, and improved long- term efficacy. Untreated depression has a significant impact by adversely affecting a patient's daily life and increasing the risk of suicide.
| File | File size |
|---|---|
| Affectis - BayTB July 8 2009 | 23 Kb |
02 April 2009
Martinsried, Germany - Affectis Pharmaceuticals, a biopharmaceutical company developing innovative drugs to treat depression and schizophrenia, has been granted two additional patents by the European Union.
The first patent, EP 1 469 072, relates to the broad and novel use of agonists targeting the ion channel P2X7 for the treatment of depression and bipolar affective disorders. A second patent, EP 1 473 367, focuses on the use of polymorphisms in P2X7 for the diagnosis of mood disorders.
The patents are supported by human association studies involving more than 2.000 depressed patients from Canada and Germany, as well as significant additional biological data validating P2X7’s role in the etiology of depression.
P2X7 may be one of a very small number of human depression genes, and the development of therapeutics acting on the target has the potential to radically improve the treatment of depression. With the granting of these comprehensive patents, Affectis has secured exclusive right in Europe to this entire therapeutic approach.
| File | File size |
|---|---|
| Affectis - Patent Update_02Apr09.pdf | 18 Kb |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.
